First Mercantile Trust’s Celldex Therapeutics CLDX Stock Holding History

First Mercantile Trust’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$117K	Sell	2,162 -758	-26%	-$35.6K	0.02%	605
2021 Q2	$98K	Sell	2,920 -594	-17%	-$16.3K	0.01%	691
2021 Q1	$72K	Buy	+3,514	New	+$80.7K	0.01%	739
2017 Q3	–	Sell	-666	Closed	-$25K	–	794
2017 Q2	$25K	Sell	666 -215	-24%	-$9.51K	﹤0.01%	804
2017 Q1	$48K	Sell	881 -66	-7%	-$3.44K	0.01%	791
2016 Q4	$50K	Sell	947 -93	-9%	-$5.29K	0.01%	798
2016 Q3	$63K	Sell	1,040 -116	-10%	-$7.22K	0.01%	781
2016 Q2	$76K	Sell	1,156 -83	-7%	-$5.27K	0.01%	796
2016 Q1	$70K	Buy	+1,239	New	+$139K	0.01%	800
2015 Q2	–	Sell	-927	Closed	-$388K	–	988
2015 Q1	$388K	Sell	927 -90	-9%	-$32.2K	0.03%	579
2014 Q4	$278K	Buy	+1,017	New	+$253K	0.02%	630
2014 Q2	–	Sell	-593	Closed	-$157K	–	1211
2014 Q1	$157K	Sell	593 -1,291	-69%	-$494K	0.01%	851
2013 Q4	$684K	Sell	1,884 -191	-9%	-$73.6K	0.05%	488
2013 Q3	$1.1M	Buy	2,075 +648	+45%	+$222K	0.09%	334
2013 Q2	$334K	Buy	+1,427	New	+$281K	0.03%	635

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

First Mercantile Trust's CLDX Position: Q3 2021 in Review

First Mercantile Trust reduced its Celldex Therapeutics (CLDX) stake by 26% in Q3 2021, selling an estimated $35.6K and leaving 2,162 shares worth $117K. The position accounts for 0.02% of the portfolio, ranked #605.

First Mercantile Trust first reported a position in CLDX in Q2 2013 and has held it in 15 quarters since. The position peaked at $1.1M in Q3 2013. 160 funds tracked by Wall St. Rank hold CLDX as of Q3 2021.

First Mercantile Trust held 2,162 shares of Celldex Therapeutics worth $117K as of Q3 2021.
First Mercantile Trust sold 758 Celldex Therapeutics shares in Q3 2021, an estimated $35.6K.
Celldex Therapeutics made up 0.02% of First Mercantile Trust's portfolio in Q3 2021, its #605 holding.
First Mercantile Trust first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 15 quarters since.
First Mercantile Trust's Celldex Therapeutics position peaked at $1.1M in Q3 2013.
160 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2021.

Based on First Mercantile Trust's 13F filing for Q3 2021, filed 24 Nov 2021.